chronic kidney disease. A clinical update from kidney disease: improving global outcomes
(KDIGO). Kidney Int 80(11):1122–1137
Norris RL, Martin JH, Thompson E et al (2010) Current status of therapeutic drug monitoring in
Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and
professional development. Ther Drug Monit 32(5):615–623
Ong FS, Das K, Wang J et al (2012) Personalized medicine and pharmacogenetic biomarkers:
progress in molecular oncology testing. Expert Rev Mol Diagn 12(6):593–602. doi:10.1586/
erm.12.59
Peria ́~nez-Pa ́rraga L, Martı ́nez-Lo ́pez I, Ventayol-Bosch P, Puigvento ́s-Latorre F, Delgado-
Sa ́nchez O (2012) Drug dosage recommendations in patients with chronic liver disease. Rev
Esp Enferm Dig 104(4):165–184
Schwab M, Schaeffeler E (2012) Pharmacogenomics: a key component of personalized therapy.
Genome Med 4(11):93. doi:10.1186/gm394
Sim SC, Kacevska M, Ingelman-Sundberg M (2013) Pharmacogenomics of drug-metabolizing
enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics
J 13(1):1–11. doi:10.1038/tpj.2012.45
Spear BB, Heath-Chiozzi M, Huff J (2001) Clinical application of pharmacogenetics. Trends Mol
Med 7(5):201–204
Stingl JC, Bartels H, Viviani R et al (2014) Relevance of UDP-glucuronosyltransferase poly-
morphisms for drug dosing: a quantitative systematic review. Pharmacol Ther 141(1):92–116.
doi:10.1016/j.pharmthera.2013.09.002
Swen JJ, Nijenhuis M, de Boer A et al (2011) Pharmacogenetics: from bench to byte—an update of
guidelines. Clin Pharmacol Ther 89(5):662–673. doi:10.1038/clpt.2011.34
Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunc-
tion. Eur J Clin Pharmacol 64(12):1147–1161
Verbeeck RK, Musuamba FT (2009) Pharmacokinetics and dosage adjustment in patients with
renal dysfunction. Eur J Clin Pharmacol 65(8):757–773
278 D. Vitezic ́et al.